{"product_id":"gavinium-mint-sugar-free-chewable-tablets-24-tablets","title":"Gavinium Mint Sugar-Free Chewable Tablets 24 Tablets","description":"\u003cdiv class=\"qMYqUG_convSearchResultHighlightRoot\"\u003e\n\u003cdiv class=\"\" data-turn-id-container=\"d14811fb-bece-409e-a364-4ce1d28fca0f\" data-is-intersecting=\"true\"\u003e\n\u003cdiv class=\"relative w-full overflow-visible\"\u003e\n\u003csection class=\"text-token-text-primary w-full focus:outline-none [--shadow-height:45px] has-data-writing-block:pointer-events-none has-data-writing-block:-mt-(--shadow-height) has-data-writing-block:pt-(--shadow-height) [\u0026amp;:has([data-writing-block])\u0026gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]\" dir=\"auto\" data-turn-id=\"d14811fb-bece-409e-a364-4ce1d28fca0f\" data-turn-id-container=\"d14811fb-bece-409e-a364-4ce1d28fca0f\" data-testid=\"conversation-turn-2\" data-scroll-anchor=\"false\" data-turn=\"assistant\"\u003e\n\u003cdiv class=\"text-base my-auto mx-auto pb-10 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm\/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg\/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)\"\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group\/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn\"\u003e\n\u003cdiv class=\"flex max-w-full flex-col gap-4 grow\"\u003e\n\u003cdiv data-message-author-role=\"assistant\" data-message-id=\"28aa759b-1e1a-429a-a37a-4415f78ead6f\" data-turn-start-message=\"true\" dir=\"auto\" data-message-model-slug=\"gpt-5-5-thinking\" class=\"min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+\u0026amp;]:mt-1\" tabindex=\"0\"\u003e\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden\"\u003e\n\u003cdiv class=\"markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling\"\u003e\n\u003cp data-start=\"58\" data-end=\"379\"\u003e\u003cstrong data-start=\"58\" data-end=\"73\"\u003eDescription\u003c\/strong\u003e\u003cbr data-start=\"73\" data-end=\"76\"\u003eGavinium Mint Sugar-Free Chewable Tablets are a medicine used to relieve symptoms of acid reflux and gastroesophageal reflux disease, including heartburn, acid regurgitation, and difficult digestion. They are especially useful after meals, at bedtime, or during pregnancy when reflux symptoms may occur.\u003c\/p\u003e\n\u003cp data-start=\"381\" data-end=\"559\"\u003eThe formula combines sodium alginate, sodium bicarbonate, and calcium carbonate to help neutralize excess stomach acid and form a protective barrier that helps limit acid reflux.\u003c\/p\u003e\n\u003cp data-start=\"561\" data-end=\"823\"\u003e\u003cstrong data-start=\"561\" data-end=\"573\"\u003eBenefits\u003c\/strong\u003e\u003cbr data-start=\"573\" data-end=\"576\"\u003eHelps relieve heartburn\u003cbr data-start=\"599\" data-end=\"602\"\u003eHelps reduce acid reflux and acid regurgitation\u003cbr data-start=\"649\" data-end=\"652\"\u003eSugar-free mint flavor\u003cbr data-start=\"674\" data-end=\"677\"\u003eSuitable for adults and adolescents from 12 years old\u003cbr data-start=\"730\" data-end=\"733\"\u003eMay be used during pregnancy and breastfeeding, with treatment kept as short as possible\u003c\/p\u003e\n\u003cp data-start=\"825\" data-end=\"956\"\u003e\u003cstrong data-start=\"825\" data-end=\"867\"\u003eActive Ingredients per Chewable Tablet\u003c\/strong\u003e\u003cbr data-start=\"867\" data-end=\"870\"\u003eSodium Alginate: 250 mg\u003cbr data-start=\"893\" data-end=\"896\"\u003eSodium Bicarbonate: 106.5 mg\u003cbr data-start=\"924\" data-end=\"927\"\u003eCalcium Carbonate: 187.5 mg\u003c\/p\u003e\n\u003cp data-start=\"958\" data-end=\"1043\"\u003e\u003cstrong data-start=\"958\" data-end=\"980\"\u003eDirections for Use\u003c\/strong\u003e\u003cbr data-start=\"980\" data-end=\"983\"\u003eFor oral use. Chew the tablets thoroughly before swallowing.\u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cstrong\u003e\u003cspan style=\"font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; color: #ff2a00;\"\u003ePlease read the following full disclosure before purchasing or using this product.\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"font-family: 'Arial',sans-serif;\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-section-id=\"rh4bgl\" data-start=\"0\" data-end=\"37\"\u003eSUMMARY OF PRODUCT CHARACTERISTICS\u003c\/h2\u003e\n\u003cp data-start=\"39\" data-end=\"69\"\u003e\u003cstrong data-start=\"39\" data-end=\"69\"\u003eANSM – Updated: 11\/02\/2026\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch2 data-section-id=\"1q9mf6y\" data-start=\"71\" data-end=\"106\"\u003e1. NAME OF THE MEDICINAL PRODUCT\u003c\/h2\u003e\n\u003cp data-start=\"108\" data-end=\"203\"\u003e\u003cstrong data-start=\"108\" data-end=\"203\"\u003eGAVINIUM MINT SUGAR-FREE, chewable tablet sweetened with aspartame and acesulfame potassium\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch2 data-section-id=\"kvb10c\" data-start=\"205\" data-end=\"251\"\u003e2. QUALITATIVE AND QUANTITATIVE COMPOSITION\u003c\/h2\u003e\n\u003cp data-start=\"253\" data-end=\"283\"\u003eEach chewable tablet contains:\u003c\/p\u003e\n\u003cp data-start=\"285\" data-end=\"383\"\u003e\u003cstrong data-start=\"285\" data-end=\"305\"\u003eSodium Alginate:\u003c\/strong\u003e 250 mg\u003cbr data-start=\"312\" data-end=\"315\"\u003e\u003cstrong data-start=\"315\" data-end=\"338\"\u003eSodium Bicarbonate:\u003c\/strong\u003e 106.5 mg\u003cbr data-start=\"347\" data-end=\"350\"\u003e\u003cstrong data-start=\"350\" data-end=\"372\"\u003eCalcium Carbonate:\u003c\/strong\u003e 187.5 mg\u003c\/p\u003e\n\u003cp data-start=\"385\" data-end=\"545\"\u003e\u003cstrong data-start=\"385\" data-end=\"418\"\u003eExcipients with known effect:\u003c\/strong\u003e one chewable tablet contains 5.86 mg of aspartame (E951), 0.375 mg of azorubine aluminum lake (E122), and 55.936 mg of sodium.\u003c\/p\u003e\n\u003cp data-start=\"547\" data-end=\"596\"\u003eFor the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003ch2 data-section-id=\"qp2fhl\" data-start=\"598\" data-end=\"623\"\u003e3. PHARMACEUTICAL FORM\u003c\/h2\u003e\n\u003cp data-start=\"625\" data-end=\"641\"\u003eChewable tablet.\u003c\/p\u003e\n\u003cp data-start=\"643\" data-end=\"889\"\u003eA 15 mm, flat, circular, two-layer chewable tablet with beveled edges. One side of the chewable tablet is pink, slightly speckled, and marked “GDA” on the surface. The other side is white with a surface marking in the shape of a sword and circle.\u003c\/p\u003e\n\u003ch2 data-section-id=\"10a89qs\" data-start=\"891\" data-end=\"917\"\u003e4. CLINICAL PARTICULARS\u003c\/h2\u003e\n\u003ch3 data-section-id=\"1bj74ou\" data-start=\"919\" data-end=\"950\"\u003e4.1 Therapeutic indications\u003c\/h3\u003e\n\u003cp data-start=\"952\" data-end=\"1121\"\u003eTreatment of symptoms of gastroesophageal reflux related to acidity, such as heartburn, acid regurgitation, and indigestion, for example after meals or during pregnancy.\u003c\/p\u003e\n\u003cp data-start=\"1123\" data-end=\"1197\"\u003eThis medicine is indicated for adults and children aged 12 years and over.\u003c\/p\u003e\n\u003ch3 data-section-id=\"qx7qdi\" data-start=\"1199\" data-end=\"1242\"\u003e4.2 Dosage and method of administration\u003c\/h3\u003e\n\u003cp data-start=\"1244\" data-end=\"1254\"\u003e\u003cstrong data-start=\"1244\" data-end=\"1254\"\u003eDosage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"1256\" data-end=\"1379\"\u003eAdults and children aged 12 years and over: 2 to 4 chewable tablets after main meals and at bedtime, up to 4 times per day.\u003c\/p\u003e\n\u003cp data-start=\"1381\" data-end=\"1405\"\u003e\u003cstrong data-start=\"1381\" data-end=\"1405\"\u003ePediatric population\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"1407\" data-end=\"1496\"\u003eChildren under 12 years old: treatment of children under 12 years old is not recommended.\u003c\/p\u003e\n\u003cp data-start=\"1498\" data-end=\"1518\"\u003e\u003cstrong data-start=\"1498\" data-end=\"1518\"\u003eElderly patients\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"1520\" data-end=\"1571\"\u003eNo dose adjustment is required for this population.\u003c\/p\u003e\n\u003cp data-start=\"1573\" data-end=\"1595\"\u003e\u003cstrong data-start=\"1573\" data-end=\"1595\"\u003eHepatic impairment\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"1597\" data-end=\"1628\"\u003eNo dose adjustment is required.\u003c\/p\u003e\n\u003cp data-start=\"1630\" data-end=\"1650\"\u003e\u003cstrong data-start=\"1630\" data-end=\"1650\"\u003eRenal impairment\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"1652\" data-end=\"1730\"\u003eUse with caution if a very strict salt-free diet is required. See section 4.4.\u003c\/p\u003e\n\u003cp data-start=\"1732\" data-end=\"1760\"\u003e\u003cstrong data-start=\"1732\" data-end=\"1760\"\u003eMethod of administration\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"1762\" data-end=\"1801\"\u003eOral use, after being carefully chewed.\u003c\/p\u003e\n\u003cp data-start=\"1803\" data-end=\"1828\"\u003e\u003cstrong data-start=\"1803\" data-end=\"1828\"\u003eDuration of treatment\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"1830\" data-end=\"2002\"\u003eThe maximum recommended duration of use without medical advice is 7 days. If symptoms do not improve after 7 days of treatment, the clinical situation should be reassessed.\u003c\/p\u003e\n\u003ch3 data-section-id=\"idzai5\" data-start=\"2004\" data-end=\"2029\"\u003e4.3 Contraindications\u003c\/h3\u003e\n\u003cp data-start=\"2031\" data-end=\"2142\"\u003eKnown or suspected hypersensitivity to the active substances or to any of the excipients listed in section 6.1.\u003c\/p\u003e\n\u003ch3 data-section-id=\"1kjthcs\" data-start=\"2144\" data-end=\"2192\"\u003e4.4 Special warnings and precautions for use\u003c\/h3\u003e\n\u003cp data-start=\"2194\" data-end=\"2292\"\u003eIf symptoms do not improve after 7 days of treatment, the clinical situation should be reassessed.\u003c\/p\u003e\n\u003cp data-start=\"2294\" data-end=\"2326\"\u003eProlonged use should be avoided.\u003c\/p\u003e\n\u003cp data-start=\"2328\" data-end=\"2528\"\u003eAs with other antacid products, taking \u003cstrong data-start=\"2367\" data-end=\"2462\"\u003eGAVINIUM MINT SUGAR-FREE, chewable tablet sweetened with aspartame and acesulfame potassium\u003c\/strong\u003e may mask the symptoms of other, more serious underlying diseases.\u003c\/p\u003e\n\u003cp data-start=\"2530\" data-end=\"2668\"\u003e\u003cstrong data-start=\"2530\" data-end=\"2668\"\u003eGAVINIUM MINT SUGAR-FREE, chewable tablet sweetened with aspartame and acesulfame potassium should not be used in the following cases:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"2670\" data-end=\"2768\"\u003ePatients with severe kidney failure or impaired kidney function.\u003cbr data-start=\"2734\" data-end=\"2737\"\u003ePatients with hypophosphatemia.\u003c\/p\u003e\n\u003cp data-start=\"2770\" data-end=\"2848\"\u003eEffectiveness may be reduced in patients with very low levels of stomach acid.\u003c\/p\u003e\n\u003cp data-start=\"2850\" data-end=\"2874\"\u003e\u003cstrong data-start=\"2850\" data-end=\"2874\"\u003ePediatric population\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"2876\" data-end=\"2981\"\u003eThere is an increased risk of hypernatremia in children with gastroenteritis or suspected kidney failure.\u003c\/p\u003e\n\u003cp data-start=\"2983\" data-end=\"3043\"\u003eTreatment of children under 12 years old is not recommended.\u003c\/p\u003e\n\u003cp data-start=\"3045\" data-end=\"3238\"\u003eThis medicine contains 223.7 mg, or 9.728 mmol, of sodium per four chewable tablets. This is equivalent to 11.18% of the WHO-recommended maximum daily dietary intake of 2 g sodium for an adult.\u003c\/p\u003e\n\u003cp data-start=\"3240\" data-end=\"3578\"\u003eThe maximum daily dose of this medicine is equivalent to 44.75% of the WHO-recommended maximum daily sodium intake. This medicine is considered to have a high sodium content. This should be taken into particular account for patients following a low-sodium diet, for example in certain cases of congestive heart failure and kidney failure.\u003c\/p\u003e\n\u003cp data-start=\"3580\" data-end=\"3782\"\u003eFour chewable tablets contain 300 mg, or 7.5 mmol, of calcium. Particular care should be taken when treating patients with hypercalcemia, nephrocalcinosis, or recurrent calcium-containing kidney stones.\u003c\/p\u003e\n\u003cp data-start=\"3784\" data-end=\"3876\"\u003eThis medicine contains azorubine aluminum lake (E122), which may cause an allergic reaction.\u003c\/p\u003e\n\u003cp data-start=\"3878\" data-end=\"4045\"\u003eThis medicine contains 5.86 mg of aspartame per chewable tablet. Due to its aspartame content (E951), this medicine must not be given to patients with phenylketonuria.\u003c\/p\u003e\n\u003ch3 data-section-id=\"6z1n2w\" data-start=\"4047\" data-end=\"4127\"\u003e4.5 Interaction with other medicinal products and other forms of interaction\u003c\/h3\u003e\n\u003cp data-start=\"4129\" data-end=\"4292\"\u003eDue to the presence of calcium and carbonates, which act as antacids, a 2-hour interval should be observed between taking this medicine and taking other medicines.\u003c\/p\u003e\n\u003cp data-start=\"4294\" data-end=\"4594\"\u003eThis applies in particular to H2 antihistamines, tetracyclines, digoxin, fluoroquinolones, iron salts, thyroid hormones, ketoconazole, neuroleptics, thyroxine, penicillamine, beta-blockers such as atenolol, metoprolol, and propranolol, glucocorticoids, chloroquine, estramustine, and bisphosphonates.\u003c\/p\u003e\n\u003cp data-start=\"4596\" data-end=\"4617\"\u003eSee also section 4.4.\u003c\/p\u003e\n\u003ch3 data-section-id=\"1jkqw0z\" data-start=\"4619\" data-end=\"4665\"\u003e4.6 Fertility, pregnancy and breastfeeding\u003c\/h3\u003e\n\u003cp data-start=\"4667\" data-end=\"4680\"\u003e\u003cstrong data-start=\"4667\" data-end=\"4680\"\u003ePregnancy\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"4682\" data-end=\"4845\"\u003eA moderate amount of data on pregnant women, between 300 and 1,000 pregnancies, has not shown any malformative or fetal\/neonatal toxicity of the active substances.\u003c\/p\u003e\n\u003cp data-start=\"4847\" data-end=\"4981\"\u003eBased on this experience and previous experience, the medicine may be used during pregnancy and breastfeeding if clinically necessary.\u003c\/p\u003e\n\u003cp data-start=\"4983\" data-end=\"5107\"\u003eHowever, due to the presence of calcium carbonate, it is recommended to keep the duration of treatment as short as possible.\u003c\/p\u003e\n\u003cp data-start=\"5109\" data-end=\"5126\"\u003e\u003cstrong data-start=\"5109\" data-end=\"5126\"\u003eBreastfeeding\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"5128\" data-end=\"5305\"\u003eNo effects of the active substances have been observed in newborns or infants breastfed by treated women. This medicine may be used during breastfeeding if clinically necessary.\u003c\/p\u003e\n\u003cp data-start=\"5307\" data-end=\"5320\"\u003e\u003cstrong data-start=\"5307\" data-end=\"5320\"\u003eFertility\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"5322\" data-end=\"5465\"\u003ePreclinical animal studies have shown that alginate has no negative effect on fertility or reproductive capacity of parents or their offspring.\u003c\/p\u003e\n\u003cp data-start=\"5467\" data-end=\"5549\"\u003eClinical data do not suggest that this medicine has any effect on human fertility.\u003c\/p\u003e\n\u003ch3 data-section-id=\"f1w6dh\" data-start=\"5551\" data-end=\"5603\"\u003e4.7 Effects on ability to drive and use machines\u003c\/h3\u003e\n\u003cp data-start=\"5605\" data-end=\"5786\"\u003e\u003cstrong data-start=\"5605\" data-end=\"5700\"\u003eGAVINIUM MINT SUGAR-FREE, chewable tablet sweetened with aspartame and acesulfame potassium\u003c\/strong\u003e has no effect or negligible effect on the ability to drive vehicles and use machines.\u003c\/p\u003e\n\u003ch3 data-section-id=\"1722mjc\" data-start=\"5788\" data-end=\"5815\"\u003e4.8 Undesirable effects\u003c\/h3\u003e\n\u003cp data-start=\"5817\" data-end=\"5969\"\u003eThe undesirable effects associated with sodium alginate, sodium bicarbonate, and calcium carbonate are listed below by system organ class and frequency.\u003c\/p\u003e\n\u003cp data-start=\"5971\" data-end=\"6197\"\u003eFrequencies are defined as follows: very common (≥1\/10), common (≥1\/100 and \u0026lt;1\/10), uncommon (≥1\/1,000 and \u0026lt;1\/100), rare (≥1\/10,000 and \u0026lt;1\/1,000), very rare (\u0026lt;1\/10,000), not known (cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp data-start=\"6199\" data-end=\"6297\"\u003eWithin each frequency group, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp data-start=\"6299\" data-end=\"6427\"\u003e\u003cstrong data-start=\"6299\" data-end=\"6326\"\u003eImmune system disorders\u003c\/strong\u003e\u003cbr data-start=\"6326\" data-end=\"6329\"\u003eVery rare: anaphylactic and anaphylactoid reactions; hypersensitivity reactions such as urticaria.\u003c\/p\u003e\n\u003cp data-start=\"6429\" data-end=\"6536\"\u003e\u003cstrong data-start=\"6429\" data-end=\"6467\"\u003eMetabolism and nutrition disorders\u003c\/strong\u003e\u003cbr data-start=\"6467\" data-end=\"6470\"\u003eFrequency not known: alkalosis, hypercalcemia, Burnett’s syndrome.\u003c\/p\u003e\n\u003cp data-start=\"6538\" data-end=\"6654\"\u003e\u003cstrong data-start=\"6538\" data-end=\"6589\"\u003eRespiratory, thoracic and mediastinal disorders\u003c\/strong\u003e\u003cbr data-start=\"6589\" data-end=\"6592\"\u003eFrequency not known: respiratory effects such as bronchospasm.\u003c\/p\u003e\n\u003cp data-start=\"6656\" data-end=\"6794\"\u003e\u003cstrong data-start=\"6656\" data-end=\"6686\"\u003eGastrointestinal disorders\u003c\/strong\u003e\u003cbr data-start=\"6686\" data-end=\"6689\"\u003eVery rare: abdominal pain, acid rebound, diarrhea, nausea, vomiting.\u003cbr data-start=\"6757\" data-end=\"6760\"\u003eFrequency not known: constipation.\u003c\/p\u003e\n\u003cp data-start=\"6796\" data-end=\"6868\"\u003e\u003cstrong data-start=\"6796\" data-end=\"6838\"\u003eSkin and subcutaneous tissue disorders\u003c\/strong\u003e\u003cbr data-start=\"6838\" data-end=\"6841\"\u003eVery rare: itchy skin rash.\u003c\/p\u003e\n\u003cp data-start=\"6870\" data-end=\"6915\"\u003e\u003cstrong data-start=\"6870\" data-end=\"6915\"\u003eDescription of selected adverse reactions\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"6917\" data-end=\"7007\"\u003eThese effects generally occur after administration of doses higher than those recommended.\u003c\/p\u003e\n\u003cp data-start=\"7009\" data-end=\"7050\"\u003e\u003cstrong data-start=\"7009\" data-end=\"7050\"\u003eReporting suspected adverse reactions\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"7052\" data-end=\"7444\"\u003eReporting suspected adverse reactions after authorization of the medicine is important. It allows continued monitoring of the benefit\/risk balance of the medicine. Healthcare professionals report any suspected adverse reactions via the national reporting system: Agence nationale de sécurité du médicament et des produits de santé (ANSM) and the network of Regional Pharmacovigilance Centers.\u003c\/p\u003e\n\u003cp data-start=\"7446\" data-end=\"7496\"\u003eWebsite: \u003ca data-start=\"7455\" data-end=\"7496\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/signalement.social-sante.gouv.fr\/\"\u003ehttps:\/\/signalement.social-sante.gouv.fr\/\u003cspan aria-hidden=\"true\" class=\"ms-0.5 inline-block align-middle leading-none\"\u003e\u003csvg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"20\" height=\"20\" aria-hidden=\"true\" data-rtl-flip=\"\" class=\"block h-[0.75em] w-[0.75em] stroke-current stroke-[0.75]\"\u003e\u003cuse fill=\"currentColor\" href=\"\/cdn\/assets\/sprites-core-45720d6d.svg#304883\"\u003e\u003c\/use\u003e\u003c\/svg\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3 data-section-id=\"1xn8bp2\" data-start=\"7498\" data-end=\"7514\"\u003e4.9 Overdose\u003c\/h3\u003e\n\u003cp data-start=\"7516\" data-end=\"7528\"\u003e\u003cstrong data-start=\"7516\" data-end=\"7528\"\u003eSymptoms\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"7530\" data-end=\"7647\"\u003eSymptoms will probably be minor. The patient may experience abdominal discomfort and may notice abdominal distension.\u003c\/p\u003e\n\u003cp data-start=\"7649\" data-end=\"7662\"\u003e\u003cstrong data-start=\"7649\" data-end=\"7662\"\u003eTreatment\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"7664\" data-end=\"7723\"\u003eIn case of overdose, symptomatic treatment should be given.\u003c\/p\u003e\n\u003ch2 data-section-id=\"1o7a6vr\" data-start=\"7725\" data-end=\"7757\"\u003e5. PHARMACOLOGICAL PROPERTIES\u003c\/h2\u003e\n\u003ch3 data-section-id=\"r0km5v\" data-start=\"7759\" data-end=\"7793\"\u003e5.1 Pharmacodynamic properties\u003c\/h3\u003e\n\u003cp data-start=\"7795\" data-end=\"7910\"\u003ePharmacotherapeutic group: other medicines for peptic ulcer and gastroesophageal reflux disease, ATC code: A02BX13.\u003c\/p\u003e\n\u003cp data-start=\"7912\" data-end=\"8065\"\u003eThis medicine is a combination of an alginate and two antacids, calcium carbonate and sodium bicarbonate, providing a protective and neutralizing effect.\u003c\/p\u003e\n\u003cp data-start=\"8067\" data-end=\"8088\"\u003e\u003cstrong data-start=\"8067\" data-end=\"8088\"\u003eProtective effect\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"8090\" data-end=\"8277\"\u003eAfter ingestion, this medicine quickly reacts with stomach acid to form a protective barrier, or raft, of alginic acid gel with a pH close to neutral, floating above the stomach contents.\u003c\/p\u003e\n\u003cp data-start=\"8279\" data-end=\"8599\"\u003eEffective obstruction of gastroesophageal reflux may last up to 4 hours. This means acid regurgitation is mechanically prevented, thereby protecting the esophagus. In cases of severe reflux, the raft itself may be regurgitated into the esophagus instead of the stomach contents. The raft then provides a soothing effect.\u003c\/p\u003e\n\u003cp data-start=\"8601\" data-end=\"8624\"\u003e\u003cstrong data-start=\"8601\" data-end=\"8624\"\u003eNeutralizing effect\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"8626\" data-end=\"8774\"\u003eCalcium carbonate and sodium bicarbonate react immediately after ingestion to neutralize stomach acid and quickly relieve indigestion and heartburn.\u003c\/p\u003e\n\u003cp data-start=\"8776\" data-end=\"8910\"\u003e\u003cstrong data-start=\"8776\" data-end=\"8871\"\u003eGAVINIUM MINT SUGAR-FREE, chewable tablet sweetened with aspartame and acesulfame potassium\u003c\/strong\u003e neutralizes the post-meal acid pocket.\u003c\/p\u003e\n\u003cp data-start=\"8912\" data-end=\"9029\"\u003eThe total neutralizing capacity of the medicine at the lowest dose of two chewable tablets is approximately 10 mEqH+.\u003c\/p\u003e\n\u003cp data-start=\"9031\" data-end=\"9506\"\u003eThis effect was also demonstrated in an in vivo study using intragastric pH monitoring with a multi-electrode catheter in fasting healthy participants in order to eliminate variability caused by post-meal buffering. The primary endpoint of the study was the percentage of time with intragastric pH ≥ 4 during the 30 minutes following treatment. This endpoint was reached in 50.8% of cases with the sodium alginate-antacid medicine versus 3.5% of cases with placebo, p=0.0051.\u003c\/p\u003e\n\u003ch3 data-section-id=\"14s5qqa\" data-start=\"9508\" data-end=\"9542\"\u003e5.2 Pharmacokinetic properties\u003c\/h3\u003e\n\u003cp data-start=\"9544\" data-end=\"9637\"\u003eThe mode of action of this medicine is mechanical and does not depend on systemic absorption.\u003c\/p\u003e\n\u003ch3 data-section-id=\"17ccay2\" data-start=\"9639\" data-end=\"9670\"\u003e5.3 Preclinical safety data\u003c\/h3\u003e\n\u003cp data-start=\"9672\" data-end=\"9827\"\u003eThere are no preclinical data relevant to the prescriber in addition to those already included in other sections of the Summary of Product Characteristics.\u003c\/p\u003e\n\u003ch2 data-section-id=\"1dcpof2\" data-start=\"9829\" data-end=\"9861\"\u003e6. PHARMACEUTICAL PARTICULARS\u003c\/h2\u003e\n\u003ch3 data-section-id=\"ulclja\" data-start=\"9863\" data-end=\"9889\"\u003e6.1 List of excipients\u003c\/h3\u003e\n\u003cp data-start=\"9891\" data-end=\"10117\"\u003eMacrogol, Mannitol (E421), Copovidone, Acesulfame Potassium, Aspartame (E951), Azorubine Aluminum Lake (E122), Magnesium Stearate, Xylitol DC containing Sodium Carmellose, Mint Flavoring containing Maltodextrin and Gum Arabic.\u003c\/p\u003e\n\u003ch3 data-section-id=\"1svkhc3\" data-start=\"10119\" data-end=\"10144\"\u003e6.2 Incompatibilities\u003c\/h3\u003e\n\u003cp data-start=\"10146\" data-end=\"10161\"\u003eNot applicable.\u003c\/p\u003e\n\u003ch3 data-section-id=\"1av13vj\" data-start=\"10163\" data-end=\"10181\"\u003e6.3 Shelf life\u003c\/h3\u003e\n\u003cp data-start=\"10183\" data-end=\"10191\"\u003e2 years.\u003c\/p\u003e\n\u003ch3 data-section-id=\"tbnyt2\" data-start=\"10193\" data-end=\"10232\"\u003e6.4 Special precautions for storage\u003c\/h3\u003e\n\u003cp data-start=\"10234\" data-end=\"10334\"\u003eStore at a temperature not exceeding 30°C. Store in the original packaging, protected from moisture.\u003c\/p\u003e\n\u003ch3 data-section-id=\"pyqbgt\" data-start=\"10336\" data-end=\"10376\"\u003e6.5 Nature and contents of container\u003c\/h3\u003e\n\u003cp data-start=\"10378\" data-end=\"10479\"\u003eTransparent laminate blister packs made of PVC\/PE\/PVDC with aluminum foil lidding, packaged in a box.\u003c\/p\u003e\n\u003cp data-start=\"10481\" data-end=\"10536\"\u003eBlister pack containing 2, 4, 6, or 8 chewable tablets.\u003c\/p\u003e\n\u003cp data-start=\"10538\" data-end=\"10616\"\u003ePack sizes: 4, 6, 8, 12, 16, 24, 32, 48, 60, 64, 80, and 112 chewable tablets.\u003c\/p\u003e\n\u003cp data-start=\"10618\" data-end=\"10653\"\u003eNot all pack sizes may be marketed.\u003c\/p\u003e\n\u003ch3 data-section-id=\"a3s976\" data-start=\"10655\" data-end=\"10714\"\u003e6.6 Special precautions for disposal and other handling\u003c\/h3\u003e\n\u003cp data-start=\"10716\" data-end=\"10749\"\u003eNo special disposal requirements.\u003c\/p\u003e\n\u003ch2 data-section-id=\"1mp8fy3\" data-start=\"10751\" data-end=\"10787\"\u003e7. MARKETING AUTHORIZATION HOLDER\u003c\/h2\u003e\n\u003cp data-start=\"10789\" data-end=\"10873\"\u003e\u003cstrong data-start=\"10789\" data-end=\"10828\"\u003eRECKITT BENCKISER HEALTHCARE FRANCE\u003c\/strong\u003e\u003cbr data-start=\"10828\" data-end=\"10831\"\u003e38 Rue Victor Basch\u003cbr data-start=\"10850\" data-end=\"10853\"\u003e91300 Massy\u003cbr data-start=\"10864\" data-end=\"10867\"\u003eFrance\u003c\/p\u003e\n\u003ch2 data-section-id=\"1a1ujq5\" data-start=\"10875\" data-end=\"10914\"\u003e8. MARKETING AUTHORIZATION NUMBER(S)\u003c\/h2\u003e\n\u003cp data-start=\"10916\" data-end=\"11799\"\u003e34009 303 240 2 8: 4 chewable tablets in blister pack(s) (PVC\/PE\/PVDC)\u003cbr data-start=\"10986\" data-end=\"10989\"\u003e34009 303 240 3 5: 6 chewable tablets in blister pack(s) (PVC\/PE\/PVDC)\u003cbr data-start=\"11059\" data-end=\"11062\"\u003e34009 303 240 4 2: 8 chewable tablets in blister pack(s) (PVC\/PE\/PVDC)\u003cbr data-start=\"11132\" data-end=\"11135\"\u003e34009 303 240 5 9: 12 chewable tablets in blister pack(s) (PVC\/PE\/PVDC)\u003cbr data-start=\"11206\" data-end=\"11209\"\u003e34009 303 240 6 6: 16 chewable tablets in blister pack(s) (PVC\/PE\/PVDC)\u003cbr data-start=\"11280\" data-end=\"11283\"\u003e34009 303 240 7 3: 24 chewable tablets in blister pack(s) (PVC\/PE\/PVDC)\u003cbr data-start=\"11354\" data-end=\"11357\"\u003e34009 303 240 9 7: 32 chewable tablets in blister pack(s) (PVC\/PE\/PVDC)\u003cbr data-start=\"11428\" data-end=\"11431\"\u003e34009 303 241 0 3: 48 chewable tablets in blister pack(s) (PVC\/PE\/PVDC)\u003cbr data-start=\"11502\" data-end=\"11505\"\u003e34009 303 241 1 0: 60 chewable tablets in blister pack(s) (PVC\/PE\/PVDC)\u003cbr data-start=\"11576\" data-end=\"11579\"\u003e34009 303 241 2 7: 64 chewable tablets in blister pack(s) (PVC\/PE\/PVDC)\u003cbr data-start=\"11650\" data-end=\"11653\"\u003e34009 303 241 3 4: 80 chewable tablets in blister pack(s) (PVC\/PE\/PVDC)\u003cbr data-start=\"11724\" data-end=\"11727\"\u003e34009 303 241 5 8: 112 chewable tablets in blister pack(s) (PVC\/PE\/PVDC)\u003c\/p\u003e\n\u003ch2 data-section-id=\"jdv2gl\" data-start=\"11801\" data-end=\"11861\"\u003e9. DATE OF FIRST AUTHORIZATION \/ RENEWAL OF AUTHORIZATION\u003c\/h2\u003e\n\u003cp data-start=\"11863\" data-end=\"11923\"\u003eTo be completed later by the marketing authorization holder.\u003c\/p\u003e\n\u003cp data-start=\"11925\" data-end=\"11969\"\u003eDate of first authorization: {DD month YYYY}\u003c\/p\u003e\n\u003cp data-start=\"11971\" data-end=\"12008\"\u003eDate of last renewal: {DD month YYYY}\u003c\/p\u003e\n\u003ch2 data-section-id=\"9i4wsp\" data-start=\"12010\" data-end=\"12045\"\u003e10. DATE OF REVISION OF THE TEXT\u003c\/h2\u003e\n\u003cp data-start=\"12047\" data-end=\"12107\"\u003eTo be completed later by the marketing authorization holder.\u003c\/p\u003e\n\u003cp data-start=\"12109\" data-end=\"12124\"\u003e{DD month YYYY}\u003c\/p\u003e\n\u003ch2 data-section-id=\"1mt3f9p\" data-start=\"12126\" data-end=\"12142\"\u003e11. DOSIMETRY\u003c\/h2\u003e\n\u003cp data-start=\"12144\" data-end=\"12159\"\u003eNot applicable.\u003c\/p\u003e\n\u003ch2 data-section-id=\"g7mf7x\" data-start=\"12161\" data-end=\"12220\"\u003e12. INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS\u003c\/h2\u003e\n\u003cp data-start=\"12222\" data-end=\"12237\"\u003eNot applicable.\u003c\/p\u003e\n\u003ch2 data-section-id=\"1owvgm0\" data-start=\"12239\" data-end=\"12280\"\u003ePRESCRIPTION AND DISPENSING CONDITIONS\u003c\/h2\u003e\n\u003cp data-start=\"12282\" data-end=\"12336\" data-is-last-node=\"\" data-is-only-node=\"\"\u003eMedicinal product not subject to medical prescription.\u003c\/p\u003e\n\u003cp data-start=\"1045\" data-end=\"1169\"\u003eAdults and children aged 12 years and over: take 2 to 4 tablets after meals and at bedtime, up to 4 times per day as needed.\u003c\/p\u003e\n\u003cp data-start=\"1171\" data-end=\"1229\"\u003eConsult a doctor if symptoms persist for more than 7 days.\u003c\/p\u003e\n\u003cp data-start=\"1231\" data-end=\"1622\"\u003e\u003cstrong data-start=\"1231\" data-end=\"1243\"\u003eWarnings\u003c\/strong\u003e\u003cbr data-start=\"1243\" data-end=\"1246\"\u003eDo not use if you are allergic to any of the ingredients.\u003cbr data-start=\"1303\" data-end=\"1306\"\u003eAsk a doctor or pharmacist before use if you have kidney disease, heart disease, electrolyte disorders, hypophosphatemia, reduced stomach acid, or intolerance to certain sugars.\u003cbr data-start=\"1483\" data-end=\"1486\"\u003eThis product contains sodium. Use with caution if you are on a sodium-restricted diet.\u003cbr data-start=\"1572\" data-end=\"1575\"\u003eContains aspartame and azorubine aluminum lake.\u003c\/p\u003e\n\u003cp data-start=\"1624\" data-end=\"1869\"\u003e\u003cstrong data-start=\"1624\" data-end=\"1639\"\u003eIngredients\u003c\/strong\u003e\u003cbr data-start=\"1639\" data-end=\"1642\"\u003eSodium Alginate, Sodium Bicarbonate, Calcium Carbonate, Xylitol, Sodium Carmellose, Magnesium Stearate, Macrogol, Mannitol (E421), Copovidone, Acesulfame Potassium, Aspartame (E951), Mint Flavor, Azorubine Aluminum Lake (E122).\u003c\/p\u003e\n\u003cp data-start=\"1871\" data-end=\"2110\" data-is-last-node=\"\" data-is-only-node=\"\"\u003e\u003cstrong data-start=\"1871\" data-end=\"1890\"\u003eProduct Details\u003c\/strong\u003e\u003cbr data-start=\"1890\" data-end=\"1893\"\u003eBrand: Gavinium\u003cbr data-start=\"1908\" data-end=\"1911\"\u003eFormat: Chewable tablets\u003cbr data-start=\"1935\" data-end=\"1938\"\u003eFlavor: Mint\u003cbr data-start=\"1950\" data-end=\"1953\"\u003eSugar-Free: Yes\u003cbr data-start=\"1968\" data-end=\"1971\"\u003eQuantity: 24 chewable tablets\u003cbr data-start=\"2000\" data-end=\"2003\"\u003eRecommended Age: Adults and children 12 years and older\u003cbr data-start=\"2058\" data-end=\"2061\"\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"z-0 flex min-h-[46px] justify-start\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"contents\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Pharmarcie.com","offers":[{"title":"Default Title","offer_id":46250730422444,"sku":"P3400930324073","price":34.95,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0604\/4047\/7868\/files\/apic10_4d855a79-0a5d-4994-93b0-986a3850fb61.jpg?v=1778773414","url":"https:\/\/pharmarcie.com\/products\/gavinium-mint-sugar-free-chewable-tablets-24-tablets","provider":"Pharmarcie.com","version":"1.0","type":"link"}